Spero Therapeutics, Inc. (SPRO) - Latest Market Data

Price & Market Data

Price: $2.76

Daily Change: +$0.07 / 2.54%

Daily Range: $2.68 - $2.85

Market Cap: $159,808,112

Daily Volume: 534,648

Performance Metrics

1 Week: 3.32%

1 Month: -1.41%

3 Months: 17.65%

6 Months: 26.13%

1 Year: 317.2%

YTD: 20.69%

About Spero Therapeutics, Inc. (SPRO)

Quick market take on Spero Therapeutics, Inc. (SPRO). Current price: 2.76, daily change: +$0.07 / 2.54%. Market cap: 159,808,112. Performance over 1-week and 1-month.

Company Details

Employees: 25

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Selected stocks

Veea Inc. (VEEA)

Agenus Inc. (AGEN)

NioCorp Developments Ltd. (NB)

CID HoldCo, Inc. (DAIC)

InspireMD Inc. (NSPR)